Send to

Choose Destination
J Natl Compr Canc Netw. 2017 May;15(5S):726-729.

Opportunities and Challenges: Human Papillomavirus and Cancer.

Author information

Presented by Christina S. Chu, MD, Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; and David G. Pfister, MD, Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, New York.


Mucosal exposure to human papillomavirus (HPV) can lead to anogenital and head and neck (H&N) cancer. Vaccination at a young age can be almost 100% effective in preventing HPV infection with the viral subtypes in both men and women, at least for disease in the anogenital tract. Therapeutic strategies targeting HPV in cervical dysplasia and cancer are showing promise as well in regressing dysplasia and controlling disease. That HPV-positive H&N cancer is a different disease from HPV-negative disease, with different molecular and clinical features and prognosis, is becoming better appreciated. At this time, however, the NCCN Guidelines for H&N Cancers do not distinguish between the types. This is expected to change.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center